MannKind Corp at Morgan Stanley Global Healthcare Conference Transcript
Good morning. I'm Sam Jones from the Morgan Stanley team. I'm excited to have joining us today, Mike Castagna, CEO of MannKind. Before we get started, I'll read a disclaimer -- so this is research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
So Mike, thanks very much for being here today. To start off, it would be great if you could provide an introduction to MannKind, maybe a quick overview of the great progress that you've made over the last few years and where you stand as a company today.
Yes, thank you. Thanks for having us today. MannKind has been around 32 years this year. It's been a long time coming. It was originally an inhaled insulin company platform that really was repurposed back in 2017
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |